Compare Smith & Nephew plc (SNN) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs ProShares Ultra Semiconductors — how do they compare? Smith & Nephew plc trades at $27.08 (market cap $11.10B), while ProShares Ultra Semiconductors trades at $95.06 (market cap $2.94B). The key difference: Smith & Nephew plc is far larger — about 3.8× ProShares Ultra Semiconductors's market cap, and Smith & Nephew plc pays a 2.95% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and ProShares Ultra Semiconductors for 29 Days on average.
| SNN | USD | |
|---|---|---|
Market Cap | $11.10B | $2.94B |
Volume | 1,051,703 | 630,148 |
Sector | Health | Leveraged / Inverse |
52-Week High | $37.17 | $113.53 |
52-Week Low | $26.42 | $43.19 |
Typical Hold Time | 120 Days | 29 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
